Achieve Life Sciences, Inc. (NasdaqCM: QUIT)
Health Care · Biotechnology · US
$6.32
+0.48% today · +44.3% 1Y
Achieve Life Sciences, Inc. (NasdaqCM: QUIT) operates in the Biotechnology industry within the Health Care sector. The company is valued at $695.42M and employs 28 people.
Over the last twelve months the share price has gained 44.3%, trading between 2.62 and 8.64.
Tweenvest scores Achieve Life Sciences, Inc. across four factors: quality 29/100, value 72/100. Its strongest factor is value.
QUIT price history
Key figures
- Market cap
- $695.42M
- Revenue (TTM)
- —
- P/E
- -6.23
- EPS
- -1.38
- Dividend yield
- —
- Beta (5Y)
- 2.41
- 52-week high
- $8.64
- 52-week low
- $2.62
- Avg volume (3M)
- —
- Shares outstanding
- 110.03M
- Employees
- 28
- Next earnings
- —
About Achieve Life Sciences, Inc.
Achieve Life Sciences, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development and market introduction of cytisinicline. This compound is aimed at assisting with smoking cessation and nicotine dependence, with commercial activities spanning Canada, the United States, and the United Kingdom. Cytisinicline is a naturally occurring alkaloid, which functions by engaging with nicotine receptors in the brain to lessen the intensity of nicotine withdrawal symptoms. The company holds licensing agreements with Sopharma AD and the University of Bristol. Its corporate headquarters are located in Vancouver, Canada.
- ISIN
- US0044685008
- Listed since
- Oct 12, 1995
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Alphamab OncologySEHK: 9966 | $709.21M | HK$5.75 | -3.36% |
| Solid Biosciences Inc.NasdaqGS: SLDB | $708.73M | $6.35 | +1.93% |
| CARsgen Therapeutics Holdings LimitedSEHK: 2171 | $699.39M | HK$9.76 | -3.37% |
| Nuvectis Pharma, Inc.NasdaqCM: NVCT | $696.03M | $20.24 | +0.05% |
| Attovia Therapeutics, Inc.NasdaqGM: ATTO | $690.70M | $15.13 | -4.30% |
| 4D Molecular Therapeutics, Inc.NasdaqGS: FDMT | $689.52M | $12.23 | +0.95% |
| Prime Medicine, Inc.NasdaqGM: PRME | $681.67M | $3.82 | -0.13% |
| Kura Oncology, Inc.NasdaqGS: KURA | $674.39M | $7.34 | -2.00% |